|
|
||||||||
Case reports |
Department of Thoracic Surgery, St James Hospital, Beckett Street, Leeds, LS9 7TF, United Kingdom
Received 8 February 2008; received in revised form 9 March 2008; accepted 11 March 2008.
* Corresponding author. Tel.: +44 113 3925 737; fax: +44 113 3926 657. (Email: thorpyat{at}aol.com).
| Abstract |
|---|
|
|
|---|
Key Words: Palmar axillary hyperhidrosis Compensatory sweating BTX-A botox Sympathectomy
| 1. Introduction |
|---|
|
|
|---|
Sufferers of this debilitating illness are frequently embarrassed by their wet handshake and sweat stained clothes, often leading to significant psychological and social morbidity.
Treatment initially consists of topical applications of antiperspirants containing aluminium salts, tanning agents, and iontophoresis with water or anticholinergic solution. Anxiolytic drugs are also frequently prescribed, however, their value is doubtful and there is a risk of inducing dependency. Anticholinergics such as propantheline bromide have shown effectiveness. However, in therapeutic doses these cause unpleasant side effects such as drowsiness, dry mouth, dilated pupils, and constipation. Thus, many patients are forced to discontinue this management.
In view of the varying levels of success offered by these treatments the definitive treatment for axillary and palmar hyperhidrosis is sympathectomy in which destruction of the T2 and T3 ganglia is performed (Fig. 1 ).
|
| 2. Case report |
|---|
|
|
|---|
The early postoperative response was favourable, with the patient experiencing dry hands and axillae. Within 6 weeks however, the patient began to note severe symptoms of compensatory hyperhidrosis on both his trunk and legs, which prevented him from returning to work as a swimming coach.
Initial treatment of the patient's compensatory hyperhidrosis consisted of recommencing medical therapy with propantheline and propranolol. Unfortunately, this did not alleviate the symptoms. It was therefore considered that in light of the recent successful reports of the use of botulinum toxin type-A (BTX-A) for the treatment of axillary hyperhidrosis by subcutaneous injection [3], that the direct injection of the neurotoxin into the sympathetic chain below the sympathectomy could possibly cure these undesired symptoms.
Using an identical VATS approach with utilisation of the previous port sites, uneventful access to the sympathetic chain was obtained and BTX-A was injected bilaterally to both the intercostal and sympathetic ganglia from T4 to T6 (100 units per side). Recovery was unremarkable and postoperative results were extremely encouraging. The patient demonstrated a significant reduction of his symptoms on both his trunk and legs. Despite a dramatic improvement in the patient's symptoms the benefits were predominately unilateral, with some residual sweating on the left lower leg. The patient once again sought the possibility of further intervention.
He was therefore considered for an extended bilateral sympathectomy (T4–T6) 12 months after his initial sympathectomy. The procedure was performed with the patient in the lateral thoracotomy position and using the previous thoracoscopic ports. Minimal adhesions were encountered and divided using diathermy. The sympathectomy was then extended from T4 to T6 following which complete resolution of his symptoms of compensatory hyperhidrosis was noted. At follow-up clinic the patient confirmed no further issues with axillary or palmar hyperhidrosis, and was no longer troubled with compensatory hyperhidrosis.
| 3. Discussion |
|---|
|
|
|---|
A group of 265 patients followed-up post sympathectomy showed that the time course for compensatory hyperhidrosis appeared to be a dynamic phenomenon [8]. Fifty percent of patients developed it immediately following surgery, 80% after 3 months and 90% after 6 months. It was also noted that the severity of compensatory hyperhidrosis did not change with time in the majority of patients (70%), but increased in severity in 10% of patients and decreased in severity in 20% within 2 years of surgery.
Furthermore the mechanisms of compensatory hyperhidrosis have not been fully elucidated and it is debated whether or not the extent of a sympathetic resection leads to a higher or lower risk of this complication [1,9].
Our case is the first to report the use of endoscopic administration of botulinum toxin to the sympathetic chain to relieve symptoms of compensatory hyperhidrosis used in combination with T4–T6 sympathectomy.
To conclude, the use of endoscopic sympathectomy for the treatment of palmar and axillary hyperhidrosis is considered an effective treatment for this condition. However, compensatory sweating is the main limitation of sympathetic chain surgery. The use of botulinum toxin for the treatment of hyperhidrosis was first demonstrated in 1996 as a treatment for axillary hyperhidrosis. In this study, subcutaneous injections of botulinum toxin were found to selectively denervate the local sweat glands producing an anhidrotic patch [10].
This case demonstrates the successful treatment of compensatory hyperhidrosis using endoscopically administered botulinum toxin to the sympathetic chain, and thus confirms this therapy as an efficient adjunct to sympathectomy should this troublesome side effect occur.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. M. Hexsel, M. Soirefmann, T. C. Rodrigues, and D. Z. do Prado Increasing the Field Effects of Similar Doses of Clostridium botulinum Type A Toxin-Hemagglutinin Complex in the Treatment of Compensatory Hyperhidrosis Arch Dermatol, July 1, 2009; 145(7): 837 - 840. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |